Abstract
Hypertension is a rather simple phenotype characterized by an increase in systemic blood pressure above an arbitrarily defined threshold. Yet, the mechanisms leading to the increase in blood pressure are extremely complex and involved a wide variety of neurohormonal, renal, metabolic, and vascular factors. The causes of hypertension differ substantially in young children, in middle-aged men and women, and in the elderly. In children, hypertension is often the appearance of a renal or endocrine disease, whereas in adults, the large majority of patients with hypertension have an essential hypertension, a denomination reflecting that the mechanisms are not fully understood although some well-defined pathogenic factors have been described in patients with hypertension associated with diabetes mellitus, obesity, hyperaldosteronism, renovascular hypertension, or renal diseases. In the elderly, hypertension is strongly associated with factors leading to vascular aging and loss of arterial elasticity. The purpose of this chapter is to review the pathophysiology of hypertension in these different clinical situations in light of the recent literature.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2095–128.
Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290(2):199–206.
Ostchega Y, et al. Trends of elevated blood pressure among children and adolescents: data from the National Health and Nutrition Examination Survey 1988–2006. Am J Hypertens. 2009;22(1):59–67.
Barker DJ, et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. BMJ. 1989;298(6673):564–7.
Moritz KM, et al. Developmental programming of a reduced nephron endowment: more than just a baby’s birth weight. Am J Physiol Renal Physiol. 2009;296(1):F1–9.
Lurbe E, et al. Management of high blood pressure in children and adolescents: recommendations of the European Society of Hypertension. J Hypertens. 2009;27(9):1719–42.
Chiolero A, et al. Prevalence of hypertension in schoolchildren based on repeated measurements and association with overweight. J Hypertens. 2007;25(11):2209–17.
Chiolero A, et al. Discordant secular trends in elevated blood pressure and obesity in children and adolescents in a rapidly developing country. Circulation. 2009;119(4):558–65.
Portman RJ, et al. Pediatric hypertension: diagnosis, evaluation, management, and treatment for the primary care physician. Curr Probl Pediatr Adolesc Health Care. 2005;35(7):262–94.
Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9(8):459–69.
Bondanelli M, Ambrosio MR, degli Uberti EC. Pathogenesis and prevalence of hypertension in acromegaly. Pituitary. 2001;4(4):239–49.
Kamenicky P, et al. Body fluid expansion in acromegaly is related to enhanced epithelial sodium channel (ENaC) activity. J Clin Endocrinol Metab. 2011;96(7):2127–35.
Rosskopf D, et al. Genetics of arterial hypertension and hypotension. Naunyn Schmiedebergs Arch Pharmacol. 2007;374(5–6):429–69.
Stabouli S, Kotsis V, Zakopoulos N. Ambulatory blood pressure monitoring and target organ damage in pediatrics. J Hypertens. 2007;25(10):1979–86.
Guyton AC. Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models. Am J Physiol. 1990;259(5 Pt 2):R865–77.
Ivy JR, Bailey MA. Pressure natriuresis and the renal control of arterial blood pressure. J Physiol. 2014;592(Pt 18):3955–67.
Rettig R, Grisk O. The kidney as a determinant of genetic hypertension: evidence from renal transplantation studies. Hypertension. 2005;46(3):463–8.
Crowley SD, et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest. 2005;115(4):1092–9.
Curtis JJ, et al. Remission of essential hypertension after renal transplantation. N Engl J Med. 1983;309(17):1009–15.
Lifton RP, Gharavi AG, Geller DS. Molecular mechanisms of human hypertension. Cell. 2001;104(4):545–56.
Fava C, et al. 24-h ambulatory blood pressure is linked to chromosome 18q21-22 and genetic variation of NEDD4L associates with cross-sectional and longitudinal blood pressure in Swedes. Kidney Int. 2006;70(3):562–9.
Fava C, et al. Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure. Hum Mol Genet. 2008;17(3):413–8.
Kobori H, et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251–87.
Lombardi D, et al. Salt-sensitive hypertension develops after short-term exposure to Angiotensin II. Hypertension. 1999;33(4):1013–9.
Franco M, et al. Impaired pressure natriuresis resulting in salt-sensitive hypertension is caused by tubulointerstitial immune cell infiltration in the kidney. Am J Physiol Renal Physiol. 2013;304(7):F982–90.
DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev. 1997;77(1):75–197.
DiBona GF, Esler M. Translational medicine: the antihypertensive effect of renal denervation. Am J Physiol Regul Integr Comp Physiol. 2010;298(2):R245–53.
Julius S. Autonomic nervous system dysregulation in human hypertension. Am J Cardiol. 1991;67(10):3B–7.
Krum H, et al. Novel procedure- and device-based strategies in the management of systemic hypertension. Eur Heart J. 2011;32(5):537–44.
Patrono C. The PGH-synthase system and isozyme-selective inhibition. J Cardiovasc Pharmacol. 2006;47 Suppl 1:S1–6.
Harris Jr RC. Cyclooxygenase-2 inhibition and renal physiology. Am J Cardiol. 2002;89(6A):10D–7.
Harris RC, et al. Cyclooxygenase-2 is associated with the macula densa of rat kidney and increases with salt restriction. J Clin Invest. 1994;94(6):2504–10.
Lin L, et al. Role of prostanoids in renin-dependent and renin-independent hypertension. Hypertension. 1991;17(4):517–25.
Fujino T, et al. Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I2 receptor IP. J Clin Invest. 2004;114(6):805–12.
Cinotti GA, Pugliese F. Prostaglandins and hypertension. Am J Hypertens. 1989;2(2 Pt 2):10S–5.
Hornych A, et al. Thromboxane B2 in borderline and essential hypertensive patients. Prostaglandins Leukot Med. 1983;10(2):145–55.
Sowers JR, et al. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med. 2005;165(2):161–8.
Folkow B. Acute effects of pressure on resistance vessel geometry. Acta Physiol Scand. 1978;104(4):496–8.
Takeshita A, Mark AL. Decreased vasodilator capacity of forearm resistance vessels in borderline hypertension. Hypertension. 1980;2(5):610–6.
Mulvany MJ. Small artery remodelling in hypertension. Basic Clin Pharmacol Toxicol. 2012;110(1):49–55.
Bakker EN, et al. Organoid culture of cannulated rat resistance arteries: effect of serum factors on vasoactivity and remodeling. Am J Physiol Heart Circ Physiol. 2000;278(4):H1233–40.
Bakker EN, et al. Small artery remodeling depends on tissue-type transglutaminase. Circ Res. 2005;96(1):119–26.
Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323(1):27–36.
Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980;288(5789):373–6.
Konishi M, Su C. Role of endothelium in dilator responses of spontaneously hypertensive rat arteries. Hypertension. 1983;5(6):881–6.
Luscher TF, Raij L, Vanhoutte PM. Endothelium-dependent vascular responses in normotensive and hypertensive Dahl rats. Hypertension. 1987;9(2):157–63.
Panza JA, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323(1):22–7.
Miller MJ, Pinto A, Mullane KM. Impaired endothelium-dependent relaxations in rabbits subjected to aortic coarctation hypertension. Hypertension. 1987;10(2):164–70.
Taddei S, et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation. 1995;91(7):1981–7.
Huang PL, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature. 1995;377(6546):239–42.
Van Vliet BN, Chafe LL, Montani JP. Characteristics of 24 h telemetered blood pressure in eNOS-knockout and C57Bl/6J control mice. J Physiol. 2003;549(Pt 1):313–25.
Schiffrin EL. A critical review of the role of endothelial factors in the pathogenesis of hypertension. J Cardiovasc Pharmacol. 2001;38 Suppl 2:S3–6.
Kurtz A, Wagner C. Role of nitric oxide in the control of renin secretion. Am J Physiol. 1998;275(6 Pt 2):F849–62.
Yanagisawa M, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988;332(6163):411–5.
Luscher TF, Seo BG, Buhler FR. Potential role of endothelin in hypertension. Controversy on endothelin in hypertension. Hypertension. 1993;21(6 Pt 1):752–7.
Rabelink TJ, et al. Effects of endothelin-1 on renal function in humans: implications for physiology and pathophysiology. Kidney Int. 1994;46(2):376–81.
Kohan DE. Endothelins in the normal and diseased kidney. Am J Kidney Dis. 1997;29(1):2–26.
Ahn D, et al. Collecting duct-specific knockout of endothelin-1 causes hypertension and sodium retention. J Clin Invest. 2004;114(4):504–11.
Ishikawa T, et al. Positive inotropic action of novel vasoconstrictor peptide endothelin on guinea pig atria. Am J Physiol. 1988;255(4 Pt 2):H970–3.
Schiffrin EL. Vascular endothelin in hypertension. Vascul Pharmacol. 2005;43(1):19–29.
Schiffrin EL. The angiotensin-endothelin relationship: does it play a role in cardiovascular and renal pathophysiology? J Hypertens. 2003;21(12):2245–7.
Gariepy CE, et al. Salt-sensitive hypertension in endothelin-B receptor-deficient rats. J Clin Invest. 2000;105(7):925–33.
Ergul S, et al. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension. 1996;28(4):652–5.
Granger JP, et al. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension. 2001;38(3 Pt 2):718–22.
Zhou J, et al. Gestational hypoxia induces preeclampsia-like symptoms via heightened endothelin-1 signaling in pregnant rats. Hypertension. 2013;62(3):599–607.
Krum H, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med. 1998;338(12):784–90.
Nakov R, et al. Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens. 2002;15(7 Pt 1):583–9.
Flegal KM, et al. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999–2010. JAMA. 2012;307(5):491–7.
Bretzel RG. Can we further slow down the progression to end-stage renal disease in diabetic hypertensive patients? J Hypertens Suppl. 1997;15(2):S83–8.
Hall JE. The kidney, hypertension, and obesity. Hypertension. 2003;41(3 Pt 2):625–33.
Vogt B, Bochud M, Burnier M. The association of aldosterone with obesity-related hypertension and the metabolic syndrome. Semin Nephrol. 2007;27(5):529–37.
Goodfriend TL, et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43(2):358–63.
da Silva AA, et al. The role of the sympathetic nervous system in obesity-related hypertension. Curr Hypertens Rep. 2009;11(3):206–11.
Schwartz MW, et al. Central nervous system control of food intake. Nature. 2000;404(6778):661–71.
da Silva AA, do Carmo JM, Hall JE. Role of leptin and central nervous system melanocortins in obesity hypertension. Curr Opin Nephrol Hypertens. 2013;22(2):135–40.
Prior LJ, et al. Exposure to a high-fat diet alters leptin sensitivity and elevates renal sympathetic nerve activity and arterial pressure in rabbits. Hypertension. 2010;55(4):862–8.
Mark AL. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol. 2013;305(6):R566–81.
Wang ZV, Scherer PE. Adiponectin, cardiovascular function, and hypertension. Hypertension. 2008;51(1):8–14.
Ouchi N, et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003;42(3):231–4.
Tanida M, et al. Effects of adiponectin on the renal sympathetic nerve activity and blood pressure in rats. Exp Biol Med (Maywood). 2007;232(3):390–7.
Sarafidis PA, Bakris GL. Review: insulin and endothelin: an interplay contributing to hypertension development? J Clin Endocrinol Metab. 2007;92(2):379–85.
Manrique C, Lastra G, Sowers JR. New insights into insulin action and resistance in the vasculature. Ann N Y Acad Sci. 2014;1311:138–50.
de Bold AJ, et al. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci. 1981;28(1):89–94.
Iida T, et al. Brain natriuretic peptide is cosecreted with atrial natriuretic peptide from porcine cardiocytes. FEBS Lett. 1990;260(1):98–100.
Nakao K, et al. Molecular biology and biochemistry of the natriuretic peptide system. I: natriuretic peptides. J Hypertens. 1992;10(9):907–12.
Kario K, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension. 2014;63(4):698–705.
Fluckiger JP, et al. Effect of atriopeptin III on hematocrit and volemia of nephrectomized rats. Am J Physiol. 1986;251(4 Pt 2):H880–3.
Volpe M, et al. Effect of atrial natriuretic factor on blood pressure, renin, and aldosterone in Goldblatt hypertension. Hypertension. 1985;7(3 Pt 2):I43–8.
de Wardener HE. The hypothalamus and hypertension. Physiol Rev. 2001;81(4):1599–658.
John SW, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science. 1995;267(5198):679–81.
Lopez MJ, et al. Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature. 1995;378(6552):65–8.
Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fusion genes. Hypertension. 1990;16(3):301–7.
Jin HK, et al. Impaired release of atrial natriuretic factor in NaCl-loaded spontaneously hypertensive rats. Hypertension. 1988;11(6 Pt 2):739–44.
Schiffrin EL, St-Louis J, Essiambre R. Platelet binding sites and plasma concentration of atrial natriuretic peptide in patients with essential hypertension. J Hypertens. 1988;6(7):565–72.
Talartschik J, et al. Low atrial natriuretic peptide plasma concentrations in 100 patients with essential hypertension. Am J Hypertens. 1990;3(1):45–7.
Ferrari P, et al. Dysregulation of atrial natriuretic factor in hypertension-prone man. J Clin Endocrinol Metab. 1990;71(4):944–51.
Campese VM, et al. Salt intake and plasma atrial natriuretic peptide and nitric oxide in hypertension. Hypertension. 1996;28(3):335–40.
Cannone V, et al. Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study. Hypertension. 2013;62(5):860–5.
Rubattu S, Sciarretta S, Volpe M. Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases. Clin Sci (Lond). 2014;127(1):1–13.
Margolius HS, et al. Urinary kallikrein excretion in hypertension. Circ Res. 1972;31 Suppl 2:125–31.
Levy SB, et al. Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake. J Clin Invest. 1977;60(1):129–38.
Alfie ME, et al. Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. Hypertension. 1997;29(1 Pt 2):483–7.
Majima M, et al. High sensitivity to salt in kininogen-deficient brown Norway Katholiek rats. Hypertension. 1993;22(5):705–14.
Madeddu P, et al. Chronic kinin receptor blockade induces hypertension in deoxycorticosterone-treated rats. Br J Pharmacol. 1993;108(3):651–7.
Wang J, et al. Human tissue kallikrein induces hypotension in transgenic mice. Hypertension. 1994;23(2):236–43.
Berry TD, et al. A gene for high urinary kallikrein may protect against hypertension in Utah kindreds. Hypertension. 1989;13(1):3–8.
Zinner SH, et al. Familial aggregation of urinary kallikrein concentration in childhood: relation to blood pressure, race and urinary electrolytes. Am J Epidemiol. 1976;104(2):124–32.
Katori M, Majima M. Renal (tissue) kallikrein-kinin system in the kidney and novel potential drugs for salt-sensitive hypertension. Prog Drug Res. 2014;69:59–109.
Share L. Role of vasopressin in cardiovascular regulation. Physiol Rev. 1988;68(4):1248–84.
Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol. 2013;9(4):223–39.
Okada H, et al. Chronic and selective vasopressin blockade in spontaneously hypertensive rats. Am J Physiol. 1994;267(6 Pt 2):R1467–71.
Burrell LM, et al. Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat. Hypertension. 1994;23(6 Pt 1):737–43.
Burrell LM, et al. Age-dependent regulation of renal vasopressin V(1A) and V(2) receptors in rats with genetic hypertension: implications for the treatment of hypertension. J Am Soc Hypertens. 2013;7(1):3–13.
Naitoh M, et al. Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR. Am J Physiol. 1997;272(2 Pt 2):F229–34.
Weber R, et al. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. Hypertension. 1997;30(5):1121–7.
Thibonnier M, et al. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Hypertension. 1999;34(6):1293–300.
Gavras H, et al. Effects of a specific inhibitor of the vascular action of vasopressin in humans. Hypertension. 1984;6(2 Pt 2):I156–60.
Gavras H. Role of vasopressin in clinical hypertension and congestive cardiac failure: interaction with the sympathetic nervous system. Clin Chem. 1991;37(10 Pt 2):1828–30.
Harris RC. Abnormalities in renal dopamine signaling and hypertension: the role of GRK4. Curr Opin Nephrol Hypertens. 2012;21(1):61–5.
Felder RA, Jose PA. Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity. Nat Clin Pract Nephrol. 2006;2(11):637–50.
Svendsen UG. The importance of thymus in the pathogenesis of the chronic phase of hypertension in mice following partial infarction of the kidney. Acta Pathol Microbiol Scand A. 1977;85(4):539–47.
Bataillard A, et al. Antihypertensive effect of neonatal thymectomy in the genetically hypertensive LH rat. Thymus. 1986;8(6):321–30.
Idris-Khodja N, et al. Dual opposing roles of adaptive immunity in hypertension. Eur Heart J. 2014;35(19):1238–44.
Harrison DG, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132–40.
Cheng S, et al. Blood pressure tracking over the adult life course: patterns and correlates in the Framingham heart study. Hypertension. 2012;60(6):1393–9.
Burt VL, et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988–1991. Hypertension. 1995;25(3):305–13.
Bubb KJ, Khambata RS, Ahluwalia A. Sexual dimorphism in rodent models of hypertension and atherosclerosis. Br J Pharmacol. 2012;167(2):298–312.
Reckelhoff JF. Gender differences in the regulation of blood pressure. Hypertension. 2001;37(5):1199–208.
Charchar FJ, et al. Y is there a risk to being male? Trends Endocrinol Metab. 2003;14(4):163–8.
Reckelhoff JF, Zhang H, Granger JP. Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension. 1998;31(1 Pt 2):435–9.
Baltatu O, et al. Abolition of end-organ damage by antiandrogen treatment in female hypertensive transgenic rats. Hypertension. 2003;41(3 Pt 2):830–3.
Quan A, et al. Androgens augment proximal tubule transport. Am J Physiol Renal Physiol. 2004;287(3):F452–9.
Quinkler M, et al. Androgen receptor-mediated regulation of the alpha-subunit of the epithelial sodium channel in human kidney. Hypertension. 2005;46(4):787–98.
Dahl LK, et al. Role of the gonads in hypertension-prone rats. J Exp Med. 1975;142(3):748–59.
Masubuchi Y, et al. Gonadectomy-induced reduction of blood pressure in adult spontaneously hypertensive rats. Acta Endocrinol (Copenh). 1982;101(1):154–60.
Chappell MC, Yamaleyeva LM, Westwood BM. Estrogen and salt sensitivity in the female mRen(2). Lewis rat. Am J Physiol Regul Integr Comp Physiol. 2006;291(5):R1557–63.
Kang AK, Miller JA. Impact of gender on renal disease: the role of the renin angiotensin system. Clin Invest Med. 2003;26(1):38–44.
James GD, et al. Renin relationship to sex, race and age in a normotensive population. J Hypertens Suppl. 1986;4(5):S387–9.
Hollenberg NK, et al. Renal blood flow and its response to angiotensin II. An interaction between oral contraceptive agents, sodium intake, and the renin-angiotensin system in healthy young women. Circ Res. 1976;38(1):35–40.
Ellison KE, et al. Androgen regulation of rat renal angiotensinogen messenger RNA expression. J Clin Invest. 1989;83(6):1941–5.
Katz FH, Roper EF. Testosterone effect on renin system in rats. Proc Soc Exp Biol Med. 1977;155(3):330–3.
Chen YF, Naftilan AJ, Oparil S. Androgen-dependent angiotensinogen and renin messenger RNA expression in hypertensive rats. Hypertension. 1992;19(5):456–63.
Leung PS, et al. Androgen dependent expression of AT1 receptor and its regulation of anion secretion in rat epididymis. Cell Biol Int. 2002;26(1):117–22.
Miller JA, Anacta LA, Cattran DC. Impact of gender on the renal response to angiotensin II. Kidney Int. 1999;55(1):278–85.
Pechere-Bertschi A, Burnier M. Female sex hormones, salt, and blood pressure regulation. Am J Hypertens. 2004;17(10):994–1001.
Chobanian AV. Clinical practice. Isolated systolic hypertension in the elderly. N Engl J Med. 2007;357(8):789–96.
Lehoux S, et al. Pressure-induced matrix metalloproteinase-9 contributes to early hypertensive remodeling. Circulation. 2004;109(8):1041–7.
Dhingra R, et al. Relations of matrix remodeling biomarkers to blood pressure progression and incidence of hypertension in the community. Circulation. 2009;119(8):1101–7.
Nagareddy PR, et al. Inhibition of matrix metalloproteinase-2 improves endothelial function and prevents hypertension in insulin-resistant rats. Br J Pharmacol. 2012;165(3):705–15.
Jensky NE, et al. Blood pressure and vascular calcification. Hypertension. 2010;55(4):990–7.
Mente A, et al. Association of urinary sodium and potassium excretion with blood pressure. N Engl J Med. 2014;371(7):601–11.
Elliott P, et al. The INTERSALT study: main results, conclusions and some implications. Clin Exp Hypertens A. 1989;11(5–6):1025–34.
Chiolero A, Wurzner G, Burnier M. Renal determinants of the salt sensitivity of blood pressure. Nephrol Dial Transplant. 2001;16(3):452–8.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Burnier, M., Wuerzner, G. (2015). Pathophysiology of Hypertension. In: Jagadeesh, G., Balakumar, P., Maung-U, K. (eds) Pathophysiology and Pharmacotherapy of Cardiovascular Disease. Adis, Cham. https://doi.org/10.1007/978-3-319-15961-4_31
Download citation
DOI: https://doi.org/10.1007/978-3-319-15961-4_31
Publisher Name: Adis, Cham
Print ISBN: 978-3-319-15960-7
Online ISBN: 978-3-319-15961-4
eBook Packages: MedicineMedicine (R0)